- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04038021
Phosphatidylethanol-Based Contingency Management for Housing
Phosphatidylethanol-Based Contingency Management to Reduce Alcohol Use and Improve Housing Outcomes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The objective of this study is to determine whether CM intervention improves outcomes in the unstably housed population using alcohol biomarker phosphatidylethanol (PEth) and ethyl glucuronide (EtG) to test alcohol abstinence. In CM, participants receive tangible rewards for demonstrating drug abstinence while non-contingent intervention receive the rewards regardless of PEth and EtG results for alcohol.
The investigators propose to examine whether CM intervention, to reduce alcohol use to abstinence, is a feasible and acceptable treatment in supported housing. Additionally, this study will assess group differences (between PEth-based CM and non-contingent control) in alcohol abstinence, as assessed by PEth, EtG, and self-report. Characterization of group differences in housing status and other alcohol associated harms (e.g., physical and mental health, medical care, and incarceration) will also be analyzed.
A total of 20-30 participants receiving treatment as usual through Catholic Charities Spokane or other locations in the Pacific and Mountain Time Zones will take part. Participants with AUD and have PEth biomarker results above >20 ng/mL, which indicates regular alcohol usage will be randomized to
- 6 months of PEth-based CM for submitting alcohol-abstinent PEth results of 16:0/18:1 which is associated with abstinence in the past week, which is <20 ng/ml PEth biomarker in the blood when abstinent for 14-28 days. Urine EtG results will be analyzed to verify PEth result findings,
- 6 months of non-contingent control for submitting samples each week for the first 4 weeks then every 2 weeks for 4 weeks and then every 4 weeks until week 26. Control participants receive reinforcers regardless of the results of their PEth results. The primary outcomes will assess acceptability measured by attrition, Client Satisfaction Questionnaire-8 and qualitative interviews at weeks 4, 12, and 26. Other primary outcomes include assessment of the effectiveness of PEth-based CM on reducing alcohol use to abstinence and housing status.
The investigators will also be examining group differences in secondary outcomes including self-reported abstinence and heavy drinking assessed by the alcohol timeline follow back and urine EtG analyses. Other secondary outcomes include a) Addiction Severity Index Lite which assesses impact of alcohol us on psychiatric, legal, medical and family functioning, b) self-reported drug use and its severity.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Washington
-
Spokane, Washington, United States, 99202
- Catholic Charities of Eastern Washington
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Two heavy drinking episodes (Assigned Male at Birth > 4 standard drinks (SDs), Assigned Female at Birth > 3 SDs) in the prior 14 days OR >14 drinks in the past 2 weeks, confirmed by a PEth level >=20 ng/ml
- DSM-5 diagnosis of a current Alcohol Use Disorder (AUD) as assessed by the Structured Clinical Interview for Diagnostic and Statistical Manual 5 (DSM-5);
- Age >=18 years;
- Currently housed at Catholic Charities Spokane or other locations in the Pacific and Mountain time zones; and
- Previously, literally homeless or unstably housed (e.g., couch surfing) for > 1 month
Exclusion Criteria:
- Current diagnosis of substance use disorder (other than AUD and tobacco), severe;
- Inability to provide informed consent based on the MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR) and/or age over 65 and Inability to provide informed consent based on the mini-Montreal Cognitive Assessment (mini-MoCA);
- Alcohol withdrawal-related seizure or hospitalization in prior 12 months; and
- Psychiatrically or medically unsafe to participate, as assessed by the PI.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PEth-based CM
PEth-based CM participants will receive gift cards (starting at $30) each time they submit a blood spot sample (via finger prick ) with a negative alcohol result.
They will receive an additional $5 (building on the previous amount) for each additional negative alcohol result in a row.
There is a cap at $100 for each negative result.
|
In CM, tangible reinforcers are provided after individuals demonstrate biochemically verified abstinence of various substances.
CM is associated with increased abstinence from illicit drugs, nicotine, and alcohol and is the most powerful psychosocial treatment for initiating abstinence of these substances.
When participants submit a negative result for alcohol (via blood phosphatidylethanol biomarkers), the subject will receive rewards (gift cards).
In contrast, they will not receive rewards when their samples test positive for alcohol.
Other Names:
|
Active Comparator: Non-contingent Control
Non-contingent control participants will receive gift cards each visit if they provide a pinprick blood sample regardless of whether the results are positive or negative for alcohol.
Their level of reinforcement (amount in gift cards) will be equal to the average weekly CM earnings from the previous month.
|
In the non-contingent control intervention, participants will receive rewards (gift cards) regardless of the alcohol biomarker results in their samples.
Once the samples have been received, the subjects will receive reinforcers that is consistent with the average from the CM group's earnings.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Attrition to measure acceptability of PEth-based CM Intervention
Time Frame: 26 weeks of treatment (repeated measure) through study completion
|
Tolerability of PEth-based CM procedures (pinprick blood sample) measured by attendance, or attrition, with CM noted as acceptable if attrition is less than or equal to 30%.
Attrition will be defined as 1 month of no contact with study team.
|
26 weeks of treatment (repeated measure) through study completion
|
Acceptability of PEth-based CM: Client Satisfaction Questionnaire-8
Time Frame: Weeks 4, 8, 12, 16, 20, and 26; repeated measure to assess change in satisfaction through study completion
|
Administration of Client Satisfaction Questionnaire-8, a brief measure of client satisfaction that has been validated in addiction treatment.
The scale ranges from 1 to 4 with 4 indicating higher satisfaction.
Total scores therefore range from 8 (least satisfaction) to 32 (highest satisfaction).
|
Weeks 4, 8, 12, 16, 20, and 26; repeated measure to assess change in satisfaction through study completion
|
Qualitative interviews to assess satisfaction, feasibility and acceptability of PEth-based CM Intervention using Theory Domains Framework (TDF)
Time Frame: Weeks 4, 12, and 26; repeated measure to assess change in satisfaction, feasibility, and tolerability through study completion
|
Assessed by TDF to encode interviews to provide comprehensive, theory-informed data to identify determinants of satisfaction, feasibility and acceptability of intervention
|
Weeks 4, 12, and 26; repeated measure to assess change in satisfaction, feasibility, and tolerability through study completion
|
Incidence of alcohol abstinence assessed by PEth biomarker
Time Frame: Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, and 26; repeated measure to assess change through study completion
|
Efficacy of PEth-based CM in reduction of alcohol consumption to abstinence assessed by measurement of PEth in blood samples.
PEth biomarker assessed at 16:0/18:1 for 7 days or < 20 ng/ml which is consistent with 14-28 days of abstinence
|
Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, and 26; repeated measure to assess change through study completion
|
Efficacy of PEth-based CM in Stabilization of Housing Status
Time Frame: Weeks 1, 4, 8, 12, 16, 20, and 26; repeated measure to assess change of housing through study completion
|
Measured by self-report of housing status using the Residential Timeline Follow Back; includes number of days stably housed, temporarily housed, institutionally housed or literally homeless.
Residential Timeline Follow Back classifies location description of housing into literal homelessness, institutional housing, temporary housing, or stable housing.
|
Weeks 1, 4, 8, 12, 16, 20, and 26; repeated measure to assess change of housing through study completion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-Reported Alcohol Usage
Time Frame: 26 weeks of treatment (repeated measure) through study completion
|
Days self-reported abstinence, drinking or heavy drinking measured by the Alcohol Timeline Follow Back
|
26 weeks of treatment (repeated measure) through study completion
|
Alcohol Usage as measured by Urine Ethyl Glucuronide (uEtG)
Time Frame: 26 weeks of treatment (repeated measure) through study completion
|
uEtG collected and measured to determine alcohol usage in last 1-4 days; uEtG greater or equal to 300 ng/ml is identified as recent drinking occurrence
|
26 weeks of treatment (repeated measure) through study completion
|
The Addiction Severity Index Lite
Time Frame: Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
Assesses alcohol use on psychiatry, legal, medical, and family functioning, as well as self-reported drug use and its severity.
Scale ranges from 0 (no craving at all) to 4 (extreme cravings)
|
Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short-Form Health Survey-12
Time Frame: Weeks 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
Measures mental and physical functioning and overall health-related quality of life.
The scale for health includes: poor, fair, good, very good, and excellent.
The pain interference scale includes: not at all, a little bit, moderately, quite a bit, and extremely.
|
Weeks 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
Non-Study Resource Form for Medical and Criminal Justice Utilization
Time Frame: Weeks 4, 8, 12, 16, 20, and 26 through study completion
|
Measures outpatient addiction, mental health, primary care, and vocational services, as well as the emergency department, inpatient psychiatric, and medical hospitalizations, detox admissions, residential addiction treatment, arrests and incarcerations.
|
Weeks 4, 8, 12, 16, 20, and 26 through study completion
|
Substance Use Test
Time Frame: 26 weeks of treatment (repeated measure) through study completion
|
Urine samples will be tested for opioids, amphetamine, methamphetamine, cocaine, and cannabis with E-Z split (type of urine analysis cup) point-of-care immunoassays
|
26 weeks of treatment (repeated measure) through study completion
|
Cigarette Consumption
Time Frame: 26 weeks of treatment (repeated measure) through study completion
|
Assessed with the Cigarette Timeline Follow Back to measure smoking and other nicotine use
|
26 weeks of treatment (repeated measure) through study completion
|
Cognitive Functioning
Time Frame: Week 1 and 26 (repeated measure) through study completion
|
Using a battery of cognitive tests from Test My Brain
|
Week 1 and 26 (repeated measure) through study completion
|
Fagerstrom Test for Nicotine Dependence
Time Frame: 26 weeks of treatment (repeated measure) through study completion
|
Assesses an individual's dependence on nicotine; score total range from 0 to 10 with 0 being no dependence and 10 being most intense physical dependence on nicotine
|
26 weeks of treatment (repeated measure) through study completion
|
Alcohol-Related Incentive Salience
Time Frame: Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
Self-rating instrument that provides a total and two subscale scores that measure some cognitive aspects of alcohol cravings
|
Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES)
Time Frame: Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
19-item scale measuring an individual's eagerness to change drinking habits; each item has a score of 1 (strongly disagree) , 2 (disagree), 3 (not sure/undecided), 4 (agree), and 5 (strongly agree).
There are three sub-scales for recognition, ambivalence, and taking steps in relation to drinking.
The higher the score for each sub-scale indicate acknowledgement of drinking problem, uncertainty of control over drinking, and changing habits around drinking, respectively.
Lower scores indicate denial of alcohol being a problem, not wondering about control of drinking, and not taking steps to change drinking, respectively.
|
Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
Rate of Adverse Events
Time Frame: 26 weeks of treatment (repeated measure) through study completion
|
Risks related to suicidality, dangerous alcohol use and withdrawal symptoms will be assessed
|
26 weeks of treatment (repeated measure) through study completion
|
Emotional Functioning - Depression
Time Frame: Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
A questionnaire measuring the severity of depression (PHQ-9).
PQQ-9 is scored on a 4 point scale: 1 (not at all), 2 (several days), 3 (more than half the days), and 4 (nearly every day).
|
Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
Emotional Functioning - Anxiety
Time Frame: Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
A questionnaire measuring the severity of anxiety (GAD-7).
GAD-7 is scored on a 4 point scale: 1 (not at all), 2 (several days), 3 (more than half the days), and 4 (nearly every day).
|
Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
Emotional Functioning - Stress
Time Frame: Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
A questionnaire measuring the severity of stress (PSS).
The PSS is scored on a 5 point scale: 0 (Never), 1 (Almost Never), 2 (Sometimes), 3 (Fairly Often), 4 (Very Often)
|
Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17752
- R21AA027045-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use Disorder
-
Washington State UniversityRecruitingNicotine Use Disorder | Alcohol Use Disorder (AUD)United States
-
University of North Carolina, Chapel HillCompletedAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateUnited States
-
Université du Québec à Trois-RivièresCompletedAlcohol Use, Unspecified | Alcohol Use Disorder, MildCanada
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Kaiser PermanenteNORC at the University of Chicago; Agency for Healthcare Research and Quality... and other collaboratorsCompleted
-
Medical University of South CarolinaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes...RecruitingAlcohol Drinking | Substance Use | Alcohol Use Disorder | Drinking, Alcohol | Alcohol Use Disorder (AUD)United States
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Central Institute of Mental Health, MannheimNot yet recruitingAlcohol Use Disorder (AUD)Germany
-
Massachusetts General HospitalMbarara University of Science and TechnologyCompletedAlcohol Use Disorder (AUD)Uganda
-
ITAB - Institute for Advanced Biomedical TechnologiesNot yet recruitingNeurobiological Effects of Transcranial Direct Current Stimulation Treatment in Alcohol Use DisorderAlcohol Dependence | Alcohol-Related Disorders | Substance Use Disorders | Drug Abuse | Mental Disorder | Alcohol Abuse | Alcohol Use Disorder (AUD)
Clinical Trials on Phosphatidylethanol-based Contingency Management
-
University of VermontCompleted
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Aurora Health CareUniversity of Chicago; University of California, Santa CruzRecruitingOpioid Use Disorder | Cocaine Use Disorder | Methamphetamine AbuseUnited States
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
-
Medical University of South CarolinaNational Cancer Institute (NCI)Not yet recruitingTobacco Use Disorder | Nicotine Dependence
-
VA Office of Research and DevelopmentRecruitingPTSD | Cannabis-Related DisorderUnited States
-
Johns Hopkins UniversityJohns Hopkins Community PhysiciansWithdrawnSubstance-related DisorderUnited States
-
University of California, Los AngelesCompleted
-
University of VermontUnknown
-
UConn HealthNational Institute on Drug Abuse (NIDA)Completed